NCT02523092View on ClinicalTrials.gov

Use of CXCL9 as a Biomarker of Acthar Efficacy

PHASE4RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Sarcoidosis
Interventions
DRUG

Acthar gel

Acthar gel given IM or SQ as per package insert

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
lead

University of California, San Francisco

OTHER

collaborator

Mallinckrodt

INDUSTRY